A pilot randomized double-blind placebo-controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection: the pitfalls of ciprofloxacin

被引:21
|
作者
Wazait, HD
Patel, HR
van der Meulen, JHP
Ghei, M
Al-Buheissi, S
Kelsey, M
Miller, RA
Emberton, M
机构
[1] Royal Coll Surgeons England, Clin Effectiveness Unit, London WC2A 3PN, England
[2] Whittington Hosp NHS Trust, Dept Urol, London, England
[3] Whittington Hosp NHS Trust, Dept Microbiol, London, England
[4] London Sch Hyg & Trop Med, London WC1, England
关键词
catheter; urinary tract infections; nosocomial infection;
D O I
10.1111/j.1464-410X.2004.05102.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess if a short course of antibiotics starting at the time of the removing a short-term urethral catheter decreases the incidence of subsequent urinary tract infection (UTI). PATIENTS AND METHODS Patients across specialities with a urethral catheter in situ for greater than or equal to 48 h and less than or equal to 7 days were recruited at the time of catheter removal. Patients were excluded if they had had recent genitourinary surgery or were on antibiotics. Eligible patients were randomly assigned to a 48-h course of either ciprofloxacin or placebo tablets starting 2 h before catheter removal. A catheter specimen of urine was obtained before the start of the trial medication. The follow-up was at 7 and 14 days after catheter removal, with a questionnaire for UTI symptoms, and a mid-stream urine sample was taken. RESULTS Forty-eight patients were recruited and had a complete follow-up (25 received ciprofloxacin and 23 placebo). Of the ciprofloxacin group, four patients (16%) had a UTI at the follow-up after catheter removal, and two were symptomatic. The UTI in two patients (including one of those symptomatic) was newly developed after catheter removal; the other two UTIs were a result of failure to resolve a catheter-associated UTI. All these UTIs in the ciprofloxacin group were resistant to ciprofloxacin. Of the placebo group, three patients (13%) had a UTI at the follow-up after removal, and one patient was symptomatic. The UTI, newly developed after catheter removal, was resistant to ciprofloxacin. The other two patients were asymptomatic; their UTIs were a result of failure to resolve a catheter-associated UTI, and one was resistant to ciprofloxacin. CONCLUSIONS The risk of UTI (both symptomatic and asymptomatic) after removing a urethral catheter is real, even in absence of catheter-associated UTI before removal. UTIs occurring after removing a short-term urinary catheter had a high rate of resistance to ciprofloxacin. There was no detectable significant benefit in using prophylactic ciprofloxacin to reduce the UTI rate after catheter removal.
引用
收藏
页码:1048 / 1050
页数:3
相关论文
共 50 条
  • [41] Effect of Terazosin on Lower Urinary Tract Symptoms and Pain due to Double-J Stent: A Double-Blind Placebo-Controlled Randomized Clinical Trial
    Mokhtari, Gholamreza
    Shakiba, Maryam
    Ghodsi, Sara
    Farzan, Alireza
    Nejad, Sayeh Heidari
    Esmaeili, Samaneh
    UROLOGIA INTERNATIONALIS, 2011, 87 (01) : 19 - 22
  • [42] Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
    ten Doesschate, Thijs
    Kuiper, Sander
    van Nieuwkoop, Cees
    Hassing, Robert-Jan
    Ketels, Tom
    van Mens, Suzan P.
    van den Bijllaardt, Wouter
    van der Bij, Akke K.
    Geerlings, Suzanne E.
    Koster, Ad
    Koldewijn, Evert L.
    Branger, Judith
    Hoepelman, Andy I. M.
    van Werkhoven, Cornelis H.
    Bonten, Marc J. M.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (02) : 221 - 229
  • [43] Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease
    Martinuzzi, Andrea
    Liava, Alexandra
    Trevisi, Enrico
    Frare, Mara
    Tonon, Caterina
    Malucelli, Emil
    Manners, David
    Kemp, Graham J.
    Testa, Claudia
    Barbiroli, Bruno
    Lodi, Raffaele
    MUSCLE & NERVE, 2008, 37 (03) : 350 - 357
  • [44] Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: A double-blind, randomized, placebo-controlled trial
    Lin A.T.-L.
    Sun M.-J.
    Tai H.-L.
    Chuang Y.C.
    Huang S.-T.
    Wang N.
    Zhao Y.D.
    Beyrer J.
    Wulster-Radcliffe M.
    Levine L.
    Chang C.
    Viktrup L.
    BMC Urology, 8 (1)
  • [45] A randomized, double-blind, placebo-controlled pilot trial of triiodothyronine in neonatal heart surgery
    Mackie, AS
    Booth, KL
    Newburger, JW
    Gauvreau, K
    Huang, SA
    Laussen, PC
    DiNardo, JA
    del Nido, PJ
    Mayer, JE
    Jonas, RA
    McGrath, E
    Elder, J
    Roth, SJ
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (03): : 810 - 816
  • [46] Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial
    Rezaei, Farzin
    Ghaderi, Ebrahim
    Mardani, Roya
    Hamidi, Seiran
    Hassanzadeh, Kambiz
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 (03) : 282 - 289
  • [47] Progesterone and Postpartum Smoking Relapse: A Pilot Double-Blind Placebo-Controlled Randomized Trial
    Allen, Sharon S.
    Allen, Alicia M.
    Lunos, Scott
    Tosun, Nicole
    NICOTINE & TOBACCO RESEARCH, 2016, 18 (11) : 2145 - 2153
  • [48] Marfan Sartan: a randomized, double-blind, placebo-controlled trial
    Milleron, Olivier
    Arnoult, Florence
    Ropers, Jacques
    Aegerter, Philippe
    Detaint, Delphine
    Delorme, Gabriel
    Attias, David
    Tubach, Florence
    Dupuis-Girod, Sophie
    Plauchu, Henry
    Barthelet, Martine
    Sassolas, Francois
    Pangaud, Nicolas
    Naudion, Sophie
    Thomas-Chabaneix, Julie
    Dulac, Yves
    Edouard, Thomas
    Wolf, Jean-Eric
    Faivre, Laurence
    Odent, Sylvie
    Basquin, Adeline
    Habib, Gilbert
    Collignon, Patrick
    Boileau, Catherine
    Jondeau, Guillaume
    EUROPEAN HEART JOURNAL, 2015, 36 (32) : 2160 - U37
  • [49] A double-blind, randomized, placebo-controlled laser trial methodology
    Oussedik, E.
    Saleem, M. D.
    Patel, N. U.
    Feldman, S. R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : B11 - B11
  • [50] A randomized, double-blind, placebo-controlled trial of pseudoephedrine in coryza
    Latte, J
    Taverner, D
    Slobodian, P
    Shakib, S
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (07): : 429 - 432